Soluble CTLA-4 mainly produced by Treg cells inhibits type 1 inflammation without hindering type 2 immunity to allow for inflammation resolution

CTLA-4 exists as membrane (mCTLA-4) and soluble (sCTLA-4) forms. Here, we show that effector-type regulatory T cells (Tregs) are main sCTLA-4 producers in basal and inflammatory states with distinct kinetics upon TCR stimulation. Mice specifically deficient in sCTLA-4 production exhibited spontaneous activation of Th1, Th17, Tfh, and Tc1 cells, autoantibody and IgE production, M1-like macrophage polarization, and impaired wound healing. In contrast, sCTLA-4-intact mCTLA-4-deficient mice, when compared with double-deficient mice, developed milder systemic inflammation and showed predominant activation/differentiation of Th2, M2-like macrophages, and eosinophils. Consistently, recombinant sCTLA-4 inhibited in vitro differentiation of naïve T cells towards Th1 through CD80/CD86 blockade on antigen-presenting cells, but did not affect Th2 differentiation. Moreover, sCTLA-4-intact mCTLA-4-deficient Tregs effectively suppressed Th1-mediated experimental colitis whereas double-deficient Tregs did not. Thus, sCTLA-4 production by Tregs during chronic inflammation is instrumental in controlling type 1 immunity while allowing type 2 immunity to dominate and facilitate inflammation resolution.

[1]  S. Sakaguchi,et al.  Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. , 2023, Cancer cell.

[2]  Scott R. Presnell,et al.  Profiling of Tregs across tissues reveals plasticity in ST2 expression and hierarchies in tissue-specific phenotypes , 2022, iScience.

[3]  Sadashib Ghosh,et al.  Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade , 2021, Molecular Cancer.

[4]  S. Sakaguchi,et al.  Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells , 2021, Proceedings of the National Academy of Sciences.

[5]  F. Ginhoux,et al.  Genetic models of human and mouse dendritic cell development and function , 2020, Nature reviews. Immunology.

[6]  Insuk Lee,et al.  Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling , 2020, Cancer Immunology Research.

[7]  Y. Okada,et al.  Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases. , 2020, Immunity.

[8]  K. Tan,et al.  Risk variants disrupting enhancers of TH1 and TREG cells in type 1 diabetes , 2019, Proceedings of the National Academy of Sciences.

[9]  E. Newell,et al.  Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody , 2018, Proceedings of the National Academy of Sciences.

[10]  Runan Yao,et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2018, BMC Bioinformatics.

[11]  G. Gusarova,et al.  Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution , 2018, Immunity.

[12]  A. Palmer,et al.  The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes , 2018, Front. Physiol..

[13]  Richard Bonneau,et al.  c-Maf-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont , 2018, Nature.

[14]  Sen Jiang,et al.  Tim-3 Regulates Tregs’ Ability to Resolve the Inflammation and Proliferation of Acute Lung Injury by Modulating Macrophages Polarization , 2017, Shock.

[15]  M. Zenke,et al.  Differentiation of Human Induced Pluripotent Stem Cells (iPS Cells) and Embryonic Stem Cells (ES Cells) into Dendritic Cell (DC) Subsets. , 2017, Bio-protocol.

[16]  M. Neurath,et al.  Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells , 2017, Nature Medicine.

[17]  P. Hamilton,et al.  Regulatory T cells promote myelin regeneration in the Central Nervous System , 2017, Nature Neuroscience.

[18]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[19]  H. Pasolli,et al.  Impaired Epidermal to Dendritic T Cell Signaling Slows Wound Repair in Aged Skin , 2016, Cell.

[20]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[21]  R. Nurieva,et al.  T helper 2 and T follicular helper cells: Regulation and function of interleukin-4. , 2016, Cytokine & growth factor reviews.

[22]  I. Maclennan,et al.  Follicular Helper T Cells. , 2016, Annual review of immunology.

[23]  Phillip G. Popovich,et al.  Novel Markers to Delineate Murine M1 and M2 Macrophages , 2015, PloS one.

[24]  T. Fleisher.  Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4 , 2015, Pediatrics.

[25]  A. Rudensky,et al.  A Distinct Function of Regulatory T Cells in Tissue Protection , 2015, Cell.

[26]  Yoshiyuki Hizukuri,et al.  IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration. , 2015, International immunology.

[27]  K. Schäkel,et al.  IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells , 2015, Proceedings of the National Academy of Sciences.

[28]  A. Schäffer,et al.  Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations , 2014, Nature Medicine.

[29]  T. Nomura,et al.  Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease , 2014, Science.

[30]  Na‐Ra Han,et al.  TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. , 2014, The Journal of investigative dermatology.

[31]  F. Klauschen,et al.  T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization In Vivo. , 2014, Immunity.

[32]  G. Ertl,et al.  Foxp3+ CD4+ T Cells Improve Healing After Myocardial Infarction by Modulating Monocyte/Macrophage Differentiation , 2014, Circulation research.

[33]  J. Todd,et al.  Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles , 2014, The Journal of Immunology.

[34]  K. Fukuda,et al.  Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. , 2013, Journal of molecular and cellular cardiology.

[35]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[36]  Weijun Luo,et al.  Pathview: an R/Bioconductor package for pathway-based data integration and visualization , 2013, Bioinform..

[37]  R. Locksley,et al.  Eosinophils secrete IL-4 to facilitate liver regeneration , 2013, Proceedings of the National Academy of Sciences.

[38]  Hiromasa Morikawa,et al.  Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression , 2013, Proceedings of the National Academy of Sciences.

[39]  Rahul C. Deo,et al.  Type 2 Innate Signals Stimulate Fibro/Adipogenic Progenitors to Facilitate Muscle Regeneration , 2013, Cell.

[40]  R. Barker,et al.  The soluble isoform of CTLA‐4 as a regulator of T‐cell responses , 2013, European journal of immunology.

[41]  B. Vickery,et al.  TSLP Promotes Interleukin-3-independent Basophil Haematopoiesis and Type 2 Inflammation , 2012, Pediatrics.

[42]  B. Hall,et al.  IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. , 2012, Blood.

[43]  J. Hamilton,et al.  Control of macrophage lineage populations by CSF‐1 receptor and GM‐CSF in homeostasis and inflammation , 2012, Immunology and cell biology.

[44]  Fumio Takei,et al.  Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. , 2012, Immunity.

[45]  M. Kubo,et al.  The 3' enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. , 2012, Immunity.

[46]  L. Walker,et al.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.

[47]  D. Fox,et al.  Sensitivity and Resistance to Regulation by IL-4 during Th17 Maturation , 2011, The Journal of Immunology.

[48]  A. Zernecke,et al.  The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function , 2011, Diabetes.

[49]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[50]  M. Krogsgaard,et al.  Retroviral Transduction of T-cell Receptors in Mouse T-cells , 2010, Journal of visualized experiments : JoVE.

[51]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[52]  M. Bolanowski,et al.  Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. , 2009, European journal of endocrinology.

[53]  R. Locksley,et al.  IL‐18 and IL‐33 elicit Th2 cytokines from basophils via a MyD88‐ and p38α‐dependent pathway , 2009, Journal of leukocyte biology.

[54]  A. Zajícová,et al.  Distinct regulatory roles of transforming growth factor‐β and interleukin‐4 in the development and maintenance of natural and induced CD4+ CD25+ Foxp3+ regulatory T cells , 2009, Immunology.

[55]  L. Greco,et al.  A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. , 2009, International immunology.

[56]  M. Deschamps,et al.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity , 2009, Arthritis research & therapy.

[57]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[58]  Asha B. Pillai,et al.  Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. , 2009, Blood.

[59]  B. Hall,et al.  CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses. , 2009, Blood.

[60]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[61]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[62]  M. Kimura,et al.  Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. , 2008, The American journal of pathology.

[63]  P. Libby,et al.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions , 2007, The Journal of experimental medicine.

[64]  M. Neurath,et al.  Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue , 2007, Nature Protocols.

[65]  A. Varki,et al.  Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. , 2007, Blood.

[66]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[67]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[68]  Paul Pavlidis,et al.  ErmineJ: Tool for functional analysis of gene expression data sets , 2005, BMC Bioinformatics.

[69]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[70]  P. Rutgeerts,et al.  Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. , 2005, Journal of autoimmunity.

[71]  P. Tipping,et al.  CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. , 2005, Kidney international.

[72]  Hua Huang,et al.  Cutting Edge: IL-5 Primes Th2 Cytokine-Producing Capacity in Eosinophils through a STAT5-Dependent Mechanism1 , 2004, The Journal of Immunology.

[73]  Hua Huang,et al.  IL-4 Induces Differentiation and Expansion of Th2 Cytokine-Producing Eosinophils 1 , 2004, The Journal of Immunology.

[74]  E. Shevach,et al.  Activation requirements for the induction of CD4+CD25+ T cell suppressor function , 2004, European journal of immunology.

[75]  D. Wraith,et al.  Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. , 2003, Blood.

[76]  L-L Fung,et al.  Increased Expression of Soluble Cytotoxic T‐Lymphocyte‐Associated Antigen‐4 Molecule in Patients with Systemic Lupus Erythematosus , 2003, Scandinavian journal of immunology.

[77]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[78]  N. Copeland,et al.  A highly efficient recombineering-based method for generating conditional knockout mutations. , 2003, Genome research.

[79]  S. Rankin,et al.  Eotaxin-2 Generation Is Differentially Regulated by Lipopolysaccharide and IL-4 in Monocytes and Macrophages1 , 2002, The Journal of Immunology.

[80]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[81]  A. Fedorov,et al.  Structural basis for co-stimulation by the human CTLA-4/B7-2 complex , 2001, Nature.

[82]  B. Hall,et al.  IL-5 prolongs allograft survival by downregulating IL-2 and IFN-γ cytokines , 2001 .

[83]  Philippe Soriano,et al.  Widespread recombinase expression using FLPeR (Flipper) mice , 2000, Genesis.

[84]  John T. Chang,et al.  Role of Costimulation in the Induction of the IL-12/IL-12 Receptor Pathway and the Development of Autoimmunity , 2000, The Journal of Immunology.

[85]  H. Weiner,et al.  Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. , 1999, Journal of autoimmunity.

[86]  J. Schröder,et al.  Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. , 1999, American journal of respiratory cell and molecular biology.

[87]  R. Klemenz,et al.  The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. , 1998, Journal of immunology.

[88]  P. Allavena,et al.  Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. , 1998, Blood.

[89]  J. Bromberg,et al.  Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement. , 1998, Journal of immunology.

[90]  A. Mallet,et al.  IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. , 1998, Journal of immunology.

[91]  D. Green,et al.  Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.

[92]  E. Simpson,et al.  B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. , 1997, Immunity.

[93]  G. Köhler,et al.  Efficient targeting of the IL-4 gene in a BALB/c embryonic stem cell line , 1996, Transgenic Research.

[94]  P. Linsley,et al.  Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.

[95]  M. Atkinson,et al.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes , 1996, The Journal of experimental medicine.

[96]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[97]  K. Murphy,et al.  The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model , 1995, The Journal of experimental medicine.

[98]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[99]  A. Sette,et al.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  V. Kuchroo,et al.  An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. , 1995, Immunity.

[101]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[102]  P. Linsley,et al.  CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2 , 1995, The Journal of experimental medicine.

[103]  A. Sette,et al.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.

[104]  R. Coffman,et al.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.

[105]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[106]  P. Linsley,et al.  CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production , 1994, The Journal of experimental medicine.

[107]  W. Paul,et al.  Interleukin 4 suppresses interleukin 2 and interferon gamma production by naive T cells stimulated by accessory cell-dependent receptor engagement. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[108]  茂呂 和世.  Innate production of T[H]2 cytokines by adipose tissue-associated c-Kit[+]Sca-1[+] lymphoid cells , 2010 .

[109]  J. Renauld,et al.  IL-9 Induces Differentiation of TH17 Cells and Enhances Function of FoxP3+Natural Regulatory T Cells , 2009 .

[110]  M. Mack,et al.  Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease , 2003, Nature Medicine.

[111]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[112]  W. Strober,et al.  Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. , 1996, Annals of the New York Academy of Sciences.